Werewolf Therapeutics, Inc. (HOWL) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenue:
Collaboration revenue	8.1	4.5	7.3	5.0	4.1

Operating expenses:
Research and development	9.6	11.7	15.9	13.1	13.9	10.9	13.4	9.8
General and administrative	4.6	5.0	4.6	4.4	5.2	4.4	4.5	4.0
Total operating expenses	14.1	16.7	20.5	17.5	19.1	15.4	17.9	13.8
Operating loss	-6.1	-12.2	-13.2	-12.5	-15.0	-15.4	-17.9	-13.8

Other income:
Other expense, net	0.0	-1.1	-0.6	0.0	0.3	0.0		0.0
Interest income, net	1.0	1.3	1.2	0.6	0.1	0.0		0.1
Total other income	1.0	-0.9	1.2	0.6	0.4	0.0	0.0	0.0
Net loss	-5.1	-12.0	-11.9	-11.9	-14.6	-15.3	-17.9	-13.8

Net loss per share attributable to common stockholders, basic and diluted
Net loss per share, basic (usd per share)	($0.14)	($0.34)	($0.38)	($0.40)	($0.53)	($0.56)	$0.95	($0.51)
Net loss per share, diluted (usd per share)	($0.14)	($0.34)	($0.38)	($0.40)	($0.53)	($0.56)	$0.95	($0.51)

Weighted-average common shares outstanding, basic and diluted
Weighted average common shares outstanding, basic (shares)	35.6	34.8	28.9	29.8	27.5	27.4	18.5	27.2
Weighted average common shares outstanding, diluted (shares)	35.6	34.8	28.9	29.8	27.5	27.4	18.5	27.2